Puma Biotechnology Inc (NYSE:PBYI) has earned a consensus recommendation of “Buy” from the eleven research firms that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, eight have given a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $124.89.

PBYI has been the topic of several recent analyst reports. Bank of America Corporation restated a “buy” rating and set a $135.00 price objective (up from $117.00) on shares of Puma Biotechnology in a research note on Monday. Citigroup Inc. restated a “buy” rating and set a $156.00 price objective (up from $114.00) on shares of Puma Biotechnology in a research note on Thursday. J P Morgan Chase & Co restated a “buy” rating and set a $131.00 price objective on shares of Puma Biotechnology in a research note on Wednesday, October 4th. BidaskClub upgraded shares of Puma Biotechnology from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, October 3rd. Finally, Stifel Nicolaus boosted their price objective on shares of Puma Biotechnology from $110.00 to $130.00 and gave the stock a “buy” rating in a research note on Monday, October 2nd.

In related news, SVP Richard Paul Bryce sold 1,998 shares of the company’s stock in a transaction dated Thursday, July 20th. The shares were sold at an average price of $94.48, for a total value of $188,771.04. Following the transaction, the senior vice president now owns 27,246 shares in the company, valued at approximately $2,574,202.08. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Alan H. Auerbach sold 13,175 shares of the business’s stock in a transaction dated Thursday, July 20th. The shares were sold at an average price of $94.73, for a total transaction of $1,248,067.75. Following the completion of the sale, the insider now directly owns 4,170,623 shares of the company’s stock, valued at approximately $395,083,116.79. The disclosure for this sale can be found here. In the last quarter, insiders sold 45,173 shares of company stock worth $4,738,189. 22.70% of the stock is owned by company insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. FMR LLC boosted its holdings in Puma Biotechnology by 2.4% in the 1st quarter. FMR LLC now owns 3,540,729 shares of the biopharmaceutical company’s stock valued at $131,715,000 after purchasing an additional 81,410 shares during the period. Wellington Management Group LLP boosted its holdings in Puma Biotechnology by 7.2% in the 1st quarter. Wellington Management Group LLP now owns 2,539,350 shares of the biopharmaceutical company’s stock valued at $94,464,000 after purchasing an additional 170,812 shares during the period. Vanguard Group Inc. boosted its holdings in Puma Biotechnology by 1.9% in the 2nd quarter. Vanguard Group Inc. now owns 2,474,644 shares of the biopharmaceutical company’s stock valued at $216,284,000 after purchasing an additional 45,735 shares during the period. Janus Henderson Group PLC bought a new stake in Puma Biotechnology in the 2nd quarter valued at about $162,302,000. Finally, BlackRock Inc. boosted its holdings in Puma Biotechnology by 5.0% in the 2nd quarter. BlackRock Inc. now owns 1,830,342 shares of the biopharmaceutical company’s stock valued at $159,973,000 after purchasing an additional 86,924 shares during the period. 80.98% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: This news story was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this news story on another publication, it was illegally stolen and republished in violation of United States & international copyright & trademark law. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2017/10/09/brokerages-set-puma-biotechnology-inc-pbyi-target-price-at-115-33.html.

Puma Biotechnology (NYSE:PBYI) traded down 0.185% during trading on Wednesday, reaching $121.175. 627,354 shares of the company’s stock traded hands. The firm has a 50 day moving average price of $101.83 and a 200-day moving average price of $73.87. The firm’s market cap is $4.51 billion. Puma Biotechnology has a 12 month low of $28.35 and a 12 month high of $127.02.

Puma Biotechnology (NYSE:PBYI) last issued its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($2.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.32) by ($0.78). On average, analysts forecast that Puma Biotechnology will post ($8.69) earnings per share for the current fiscal year.

About Puma Biotechnology

Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.

Analyst Recommendations for Puma Biotechnology (NYSE:PBYI)

Receive News & Stock Ratings for Puma Biotechnology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology Inc and related stocks with our FREE daily email newsletter.